Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants.
Li Q, Deng X, Xu YJ, Dong L.
J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.3c00412 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för saxagliptin anhydrous. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
23 träffarA preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.
Sutherland JJ, Yonchev D, Fekete A, Urban L.
Nat Commun · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41467-023-40064-9Proline based rationally designed peptide esters against dipeptidyl peptidase-4: Highly potent anti-diabetic agents.
Vivesh, Kaur B, Jaglan S, Rani S, Batra Y, Singh P.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2022.129018A cell-based fluorescent assay for FAP inhibitor discovery.
Zhang B, Liu F, Yang MF, Xu J, Wang Z, Zhang J, Wang R, Yang X.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2020.127253In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses.
Wang Y, Hu Y, Xu S, Zhang Y, Musharrafieh R, Hau RK, Ma C, Wang J.
J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.7b01536Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes.
Zhang X, Cai C, Sui Z, Macielag M, Wang Y, Yan W, Suckow A, Hua H, Bell A, Haug P, Clapper W, Jenkinson C, Gunnet J, Leonard J, Murray WV.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.7b00233Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
Vanderheyden PML, Benachour N.
Bioorg Med Chem Lett · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.bmcl.2017.06.051Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure.
Schnapp G, Klein T, Hoevels Y, Bakker RA, Nar H.
J Med Chem · comparative study; journal article · DOI 10.1021/acs.jmedchem.6b00475DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
Drug Discov Today · review; journal article · DOI 10.1016/j.drudis.2016.02.015Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin.
Dong J, Gong Y, Liu J, Chen X, Wen X, Sun H.
Bioorg Med Chem · journal article · DOI 10.1016/j.bmc.2013.12.061Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L.
J Med Chem · review; journal article · DOI 10.1021/jm400658eSynthetic approaches to the 2011 new drugs.
Ding HX, Liu KK, Sakya SM, Flick AC, O'Donnell CJ.
Bioorg Med Chem · review; journal article · DOI 10.1016/j.bmc.2013.02.061Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
Ikuma Y, Hochigai H, Kimura H, Nunami N, Kobayashi T, Uchiyama K, Furuta Y, Sakai M, Horiguchi M, Masui Y, Okazaki K, Sato Y, Nakahira H.
Bioorg Med Chem · journal article · DOI 10.1016/j.bmc.2012.07.046Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
Su H, Boulton DW, Barros A, Wang L, Cao K, Bonacorsi SJ, Iyer RA, Humphreys WG, Christopher LJ.
Drug Metab Dispos · journal article · DOI 10.1124/dmd.112.045450Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?
Van Goethem S, Matheeussen V, Matheeussen V, Joossens J, Lambeir AM, Chen X, De Meester I, Haemers A, Augustyns K, Van der Veken P.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm200383jThe many faces of the adamantyl group in drug design.
Liu J, Obando D, Liao V, Lifa T, Codd R.
Eur J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.ejmech.2011.01.047(2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
Yeh TK, Tsai TY, Hsu T, Cheng JH, Chen X, Song JS, Shy HS, Chiou MC, Chien CH, Tseng YJ, Huang CY, Yeh KC, Huang YL, Huang CH, Huang YW, Wang MH, Tang HK, Chao YS, Chen CT, Jiaang WT.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2010.04.124Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors.
Betancort JM, Winn DT, Liu R, Xu Q, Liu J, Liao W, Chen SH, Carney D, Hanway D, Schmeits J, Li X, Gordon E, Campbell DA.
Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2009.05.048Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.
Wang L, Zhang B, Ji J, Li B, Yan J, Zhang W, Wu Y, Wang X.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2009.03.021Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
Havale SH, Pal M.
Bioorg Med Chem · review; journal article · DOI 10.1016/j.bmc.2009.01.061Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors.
Simpkins LM, Bolton S, Pi Z, Sutton JC, Kwon C, Zhao G, Magnin DR, Augeri DJ, Gungor T, Rotella DP, Sun Z, Liu Y, Slusarchyk WS, Marcinkeviciene J, Robertson JG, Wang A, Robl JA, Atwal KS, Zahler RL, Parker RA, Kirby MS, Hamann LG.
Bioorg Med Chem Lett · comparative study; validation study; journal article · DOI 10.1016/j.bmcl.2007.09.090Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
Madar DJ, Kopecka H, Pireh D, Yong H, Pei Z, Li X, Wiedeman PE, Djuric SW, Von Geldern TW, Fickes MG, Bhagavatula L, McDermott T, Wittenberger S, Richards SJ, Longenecker KL, Stewart KD, Lubben TH, Ballaron SJ, Stashko MA, Long MA, Wells H, Zinker BA, Mika AK, Beno DW, Kempf-Grote AJ, Polakowski J, Segreti J, Reinhart GA, Fryer RM, Sham HL, Trevillyan JM.
J Med Chem · journal article · DOI 10.1021/jm060777oDiscovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG.
J Med Chem · journal article · DOI 10.1021/jm050261p